MX2019012170A - Tratamiento de adipocitos. - Google Patents

Tratamiento de adipocitos.

Info

Publication number
MX2019012170A
MX2019012170A MX2019012170A MX2019012170A MX2019012170A MX 2019012170 A MX2019012170 A MX 2019012170A MX 2019012170 A MX2019012170 A MX 2019012170A MX 2019012170 A MX2019012170 A MX 2019012170A MX 2019012170 A MX2019012170 A MX 2019012170A
Authority
MX
Mexico
Prior art keywords
diabetes
type
adipocytes
syndrome
levels
Prior art date
Application number
MX2019012170A
Other languages
English (en)
Inventor
G Reaume Andrew
Cong Weina
Greenway Frank
Coulter Ann
Original Assignee
Melior Pharmaceuticals I Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Melior Pharmaceuticals I Inc filed Critical Melior Pharmaceuticals I Inc
Publication of MX2019012170A publication Critical patent/MX2019012170A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente descripción proporciona composiciones que comprenden un activador de la cinasa lyn y un agonista TRPM8 y a métodos para: reducir los niveles de glucosa en sangre, el aumento de peso o los niveles de depósito de grasa; tratar el síndrome metabólico, el síndrome X, la obesidad, la prediabetes, la diabetes tipo II, la diabetes tipo I; tratar la hipercolesterolemia, hipertensión, enfermedad coronaria, neuropatía diabética, lipodistrofia, retinopatía diabética, disfunción eréctil, enfermedad renal, dislipidemia, dislipoproteinemia, un trastorno asociado al receptor activado del proliferador de peroxisomas, septicemia, un trastorno trombótico o pancreatitis; inducir la transformación en beige de los adipocitos; y prevenir la degeneración de la células beta pancreáticas.
MX2019012170A 2017-04-10 2018-04-09 Tratamiento de adipocitos. MX2019012170A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762483584P 2017-04-10 2017-04-10
PCT/US2018/026707 WO2018191166A1 (en) 2017-04-10 2018-04-09 Treatment of adipocytes

Publications (1)

Publication Number Publication Date
MX2019012170A true MX2019012170A (es) 2020-01-20

Family

ID=63710133

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012170A MX2019012170A (es) 2017-04-10 2018-04-09 Tratamiento de adipocitos.

Country Status (13)

Country Link
US (3) US10786503B2 (es)
EP (1) EP3609500A4 (es)
JP (1) JP7182605B2 (es)
KR (1) KR102634575B1 (es)
CN (1) CN110785170B (es)
AU (1) AU2018250795B2 (es)
BR (1) BR112019021140A2 (es)
CA (1) CA3059432A1 (es)
IL (1) IL269789B (es)
MX (1) MX2019012170A (es)
SG (1) SG11201909406VA (es)
WO (1) WO2018191166A1 (es)
ZA (1) ZA201907401B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101577554B1 (ko) 2005-08-22 2015-12-14 멜리어 파마슈티칼스 아이, 인코포레이티드 Ｌｙｎ 키나제 활성의 조절 및 관련된 장애의 치료를 위한 방법 및 제제
US20130158055A1 (en) 2010-05-28 2013-06-20 Andrew G. Reaume Prevention Of Pancreatic Beta Cell Degeneration
WO2013090319A2 (en) * 2011-12-12 2013-06-20 Melior Pharmaceuticals I, Inc. Treatment of type i and type ii diabetes
CA3059432A1 (en) 2017-04-10 2018-10-18 Melior Pharmaceuticals I, Inc. Compositions comprising a lyn kinase activator and a trpms agonist
CN110302204A (zh) * 2019-07-10 2019-10-08 北京大学第三医院（北京大学第三临床医学院） 一种用于糖尿病治疗的药物
US20220031700A1 (en) * 2020-07-30 2022-02-03 Melior Pharmaceuticals I, Inc. Treatment of Acute Respiratory Distress Syndrome (ARDS)

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
BE790125A (fr) 1971-10-29 1973-04-16 Pfizer Nouvelles pyrimidinones et nouvelles hydroxypyrimidines
US3922345A (en) 1971-10-29 1975-11-25 Pfizer Pyrimidinones and hydroxy pyrimidines
US4080454A (en) 1976-07-16 1978-03-21 Pfizer Inc. 5-M-Tolyloxyuracil, anti-ulcer agent
US4612376A (en) 1983-03-25 1986-09-16 Fujisawa Pharmaceutical Co., Ltd. Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
GB9214720D0 (en) 1992-07-10 1992-08-19 Wellcome Found Enzyme inhibitors
SE9203753D0 (sv) 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
US5476855A (en) 1993-11-02 1995-12-19 Mahmoud H. el Kouni Enzyme inhibitors, their synthesis and methods for use
US6900304B2 (en) 1996-01-31 2005-05-31 The Regents Of The University Of California Emission ratiometric indicators of phosphorylation
US20020019346A1 (en) 1997-05-21 2002-02-14 Children's Medical Center Corporation Treatment of prostate cancer by inhibiting lyn tyrosine kinase
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6410255B1 (en) 1999-05-05 2002-06-25 Aurora Biosciences Corporation Optical probes and assays
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
GB0104422D0 (en) 2001-02-22 2001-04-11 Glaxo Group Ltd Quinoline derivative
US20030198666A1 (en) 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
CA2524221A1 (en) 2003-04-30 2004-11-18 The Institutes For Pharmaceutical Discovery, Llc Substituted heteroaryls as inhibitors of protein tyrosine phosphatases
US20050208054A1 (en) 2003-12-09 2005-09-22 University Of Massachusetts Methods of identifying insulin response modulators and uses therefor
EP1541694A1 (en) 2003-12-12 2005-06-15 Sirenade Pharmaceuticals AG Methods of identifying, selecting and/or characterizing compounds which modulate the activity of a Src family kinase
US20060035302A1 (en) 2004-06-21 2006-02-16 Applera Corporation Kinase substrates with multiple phosphorylation sites
US7652009B2 (en) 2004-11-30 2010-01-26 Amgem Inc. Substituted heterocycles and methods of use
WO2007016975A1 (en) 2005-07-29 2007-02-15 F. Hoffmann-La Roche Ag Kinase and phosphatase assays based on fret
US20070025953A1 (en) 2005-07-27 2007-02-01 Jones Michael R Co-therapy for diabetic conditions
KR101577554B1 (ko) 2005-08-22 2015-12-14 멜리어 파마슈티칼스 아이, 인코포레이티드 Ｌｙｎ 키나제 활성의 조절 및 관련된 장애의 치료를 위한 방법 및 제제
EP1924264B9 (en) 2005-09-01 2014-02-19 F.Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
JP2007080357A (ja) * 2005-09-13 2007-03-29 Toshiba Corp 情報記憶媒体、情報再生方法、情報再生装置
NZ579288A (en) 2007-07-23 2012-06-29 Melior Discovery Inc Methods of activating irs-1 and akt
US8552184B2 (en) * 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
WO2010078300A1 (en) * 2008-12-29 2010-07-08 The Board Of Trustees Of The University Of Alabama Dual functioning ionic liquids and salts thereof
US20130158055A1 (en) 2010-05-28 2013-06-20 Andrew G. Reaume Prevention Of Pancreatic Beta Cell Degeneration
WO2015127474A1 (en) * 2014-02-24 2015-08-27 Energesis Pharmaceuticals, Inc. Methods and compositions for inducing differentiation of human brown adipocyte progenitors
CA3059432A1 (en) 2017-04-10 2018-10-18 Melior Pharmaceuticals I, Inc. Compositions comprising a lyn kinase activator and a trpms agonist

Also Published As

Publication number Publication date
IL269789A (en) 2019-11-28
US20210128558A1 (en) 2021-05-06
SG11201909406VA (en) 2019-11-28
EP3609500A4 (en) 2020-08-19
IL269789B (en) 2022-05-01
CN110785170A (zh) 2020-02-11
US20230149404A1 (en) 2023-05-18
US20180289707A1 (en) 2018-10-11
WO2018191166A1 (en) 2018-10-18
CN110785170B (zh) 2023-03-28
BR112019021140A2 (pt) 2020-05-19
CA3059432A1 (en) 2018-10-18
US10786503B2 (en) 2020-09-29
US11534442B2 (en) 2022-12-27
JP2020513038A (ja) 2020-04-30
EP3609500A1 (en) 2020-02-19
AU2018250795B2 (en) 2022-02-10
ZA201907401B (en) 2022-03-30
AU2018250795A1 (en) 2019-11-28
JP7182605B2 (ja) 2022-12-02
KR20190133245A (ko) 2019-12-02
KR102634575B1 (ko) 2024-02-06

Similar Documents

Publication Publication Date Title
MX2019012170A (es) Tratamiento de adipocitos.
PH12019501116A1 (en) Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20
EA202091290A1 (ru) Аналоги инкретина и их применение
MX2019007584A (es) Combinaciones de compuesto de fgf21/agonista de glp-1r con una proporcion de actividades optimizada.
EA202092386A1 (ru) Конструкции на основе фактора дифференцировки и роста 15 (gdf15)
PH12020551024A1 (en) Incretin analogs and uses thereof
MX2018005193A (es) Proteinas de doble funcion y composicion farmaceutica que comprende las mismas.
PH12017500486B1 (en) Use of a long acting glp-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease
EA201792203A1 (ru) Фармацевтические композиции для комбинированной терапии
CR20190376A (es) Formulaciones de anticuerpos de her2 subcutáneas
MX2019006429A (es) Compuestos novedosos como agonistas peptidicos trigonales de los receptores de glp1/glucagon/gip.
MX2018005387A (es) Variantes de fgf21.
AU2018341571A8 (en) Therapeutic methods relating to HSP90 inhibitors
EA202190377A1 (ru) Композиции ингибиторов cxcr4 и способы получения и применения
EA201590759A1 (ru) Композиция для лечения диабета или диажирения, содержащая аналог оксинтомодулина
PH12020551656A1 (en) Growth differentiation factor 15 agonist compounds and methods of using the same
MX2011006315A (es) Analogos de glucagon.
DK2719708T3 (da) Materiale og fremgangsmåder til behandling eller forebyggelse af her-3-relaterede sygdomme
PH12015502547A1 (en) Anti-glucagon receptor antibodies and methods of use thereof
CR20210301A (es) Ácidos nucleicos para inhibir la expresión de LPA en una célula
EA202190744A1 (ru) Слитый белок glp1-fc и его конъюгат
ZA202211832B (en) Anti-glp1r antagonist antibodies and methods of use thereof
MX2022016087A (es) Anticuerpos que unen el tgf-alfa y la epirregulina para su uso en el tratamiento del dolor.
WO2019075216A8 (en) Plectin-1 binding antibodies and uses thereof
ZA202108217B (en) Lipid-based nanoparticles and use of same in optimized insulin dosing regimens